(616 - Kb)

: Both groups had roughly the same time (about 85–87 months) from their initial diagnosis until they started ibrutinib treatment. Clinical Implications

: Interestingly, the most common reason for stopping the drug was toxicity (intolerance) rather than the leukemia getting worse (disease progression). (616 KB)

: For those who stopped the medication, the median time until they did so was only 7 months . : Both groups had roughly the same time

Explain the specific (toxicities) that led to these discontinuations. Compare these results to more recent ibrutinib studies . (616 KB)

: Despite the high rate of stopping, the overall survival and progression-free survival (estimated at 35 months) remained excellent. Real-World vs. Clinical Trials